New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 5.7mg equivalent to to 5 mg ropinirole - film coated tablet - 5 mg - active: ropinirole hydrochloride 5.7mg equivalent to to 5 mg ropinirole excipient: citric acid hyprolose hypromellose indigo carmine aluminium lake lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 0.57mg equivalent to to 0.5 mg ropinirole - film coated tablet - 0.5 mg - active: ropinirole hydrochloride 0.57mg equivalent to to 0.5 mg ropinirole excipient: citric acid hyprolose hypromellose iron oxide yellow lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

New Zealand - English - Medsafe (Medicines Safety Authority)

accord healthcare nz ltd - ropinirole hydrochloride 0.57mg equivalent to 0.5 mg ropinirole - film coated tablet - 0.5 mg - active: ropinirole hydrochloride 0.57mg equivalent to 0.5 mg ropinirole excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 03b82930 - ropaccord tablets is indicated for the treatment of parkinson's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ropinirole hydrochloride 0.57mg equivalent to 0.5 mg ropinirole;  ;   - film coated tablet - 0.5 mg - active: ropinirole hydrochloride 0.57mg equivalent to 0.5 mg ropinirole     excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 85f62505 - arrow - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ropinirole hydrochloride 5.7mg equivalent to ropinirole 5 mg;   - film coated tablet - 5 mg - active: ropinirole hydrochloride 5.7mg equivalent to ropinirole 5 mg   excipient: croscarmellose sodium hypromellose   indigo carmine lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 titanium dioxide - treatment of parkinson's disease under the following conditions: - initial treatment as monotherapy, in order to delay the introduction of levodopa. - in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occurs ("end of dose" or "on-off" type fluctuations).

United States - English - NLM (National Library of Medicine)

rebel distributors corp - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - parkinson's disease: ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease. the effectiveness of ropinirole hydrochloride tablets was demonstrated in randomized, controlled trials in patients with early parkinson's disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology, clinical trials ). restless legs syndrome: ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or ni

Canada - English - Health Canada

teva canada limited - ropinirole (ropinirole hydrochloride) - tablet - 5mg - ropinirole (ropinirole hydrochloride) 5mg - nonergot-derivative dopamine receptor agonists

New Zealand - English - Medsafe (Medicines Safety Authority)

accord healthcare nz ltd - ropinirole hydrochloride 5.7mg equivalent to ropinirole 5 mg - film coated tablet - 5 mg - active: ropinirole hydrochloride 5.7mg equivalent to ropinirole 5 mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 13b50538 purified water - ropaccord tablets are indicated for the treatment of parkinson's disease.

United States - English - NLM (National Library of Medicine)

stat rx usa llc - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 1 mg - ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease. the effectiveness of ropinirole hydrochloride tablets was demonstrated in randomized, controlled trials in patients with early parkinson's disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may fr

Canada - English - Health Canada

ranbaxy pharmaceuticals canada inc. - ropinirole (ropinirole hydrochloride) - tablet - 0.25mg - ropinirole (ropinirole hydrochloride) 0.25mg - nonergot-derivative dopamine receptor agonists